IDFC
Brokerage: Morgan Stanley
Rating: Equalweight
Target: Rs 150
Rationale: RBI’s regulations on new bank licenses are unclear for NBFCs, which do not have a promoter group. Since, IDFC has no promoter, it is not clear who can form the required financial holding company, and whether it is eligible.

Ranbaxy
Brokerage: HSBC
Rating: Overweight
Target: Rs 482
Rationale: Ranbaxy's re-entry in the generic lipitor market and the approval to resume manufacturing at Ohm's labs in the US are key positive catalysts.

L&T Finance
Brokerage: JP Morgan
Rating: Neutral
Target: Rs 80
Rationale: While the stock is fully valued at the current share price, near term catalysts like a new banking license and possible rate cuts provide strong support.